Teva Hears No Again In Risperdal Spat
On Monday, the D.C. Circuit issued a written opinion in Teva's dispute with the U.S. Food and Drug Administration over Risperdal, explaining why it had sided with the agency in an expedited mandate in September.
“Teva’s abbreviated new drug application did not meet the clear and unambiguous requirements...
To view the full article, register now.